Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-RCCB6
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-NOTA-RCCB6 is a radiolabeled single-domain antibody-based immunoPET imaging agent designed to target CD70, a cell surface protein highly and specifically expressed in clear cell renal cell carcinoma (ccRCC). The molecule consists of the RCCB6 single-domain antibody conjugated with the chelator NOTA and labeled with gallium-68. Its mechanism involves binding to CD70 on tumor cells, enabling precise PET/CT imaging of primary tumors and metastases in ccRCC patients. Preclinical studies demonstrated high affinity for human CD70, rapid tumor visualization, and specificity confirmed by reduced uptake after CD70 blockade. In clinical pilot studies, 68Ga-NOTA-RCCB6 outperformed traditional 18F-FDG PET/CT in identifying CD70-positive ccRCC lesions. The agent is under investigation for its diagnostic accuracy in staging, therapeutic evaluation, and restaging of renal cell carcinoma[3][1][2][5].
- Other names
- [68Ga]Ga-NOTA-RCCB6
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on 68Ga-NOTA-RCCB6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-RCCB6.